Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Elections Drug Review FDA

Trump’s FDA Reform Agenda: Patient-Focused Approvals

  • Analysis

Executive Summary

A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.

You may also be interested in...



Top 16 From '16: Pink Sheet's Most Popular Stories

Big developments, key biopharma trends, and other topics that most intrigued and impacted our readers in 2016.

Woodcock Tries To Calm US FDA Staff Fears About Trump

CDER Director's' video advises focusing on the work and "keeping our heads down."

Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning

To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Elections Drug Review FDA
Latest Headlines

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Keeping Track: Return & Renewal At US FDA

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

See All
UsernamePublicRestriction

Register

PS119500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By